{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099891","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.642398+00:00","generated_at":"2026-05-17T23:12:44.116827+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY","bullets":["p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).","ApoE4/E4 carriers showed 20.48% mean p-tau217 reduction vs placebo (p=0.010).","Favorable trends observed in NFL, GFAP, p-tau181, and Aβ42/40 biomarkers.","Safety in BROADWAY overall was comparable to placebo; AD analysis not independently evaluated.","Company plans to discuss results with regulators and explore next steps for AD program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099891","json":"https://secwatch.observer/filing/0000950170-25-099891.json","markdown":"https://secwatch.observer/filing/0000950170-25-099891.md","text":"https://secwatch.observer/filing/0000950170-25-099891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025099891/0000950170-25-099891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025099891/nams-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:12:44.116827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}